BIIB vs GSK

Head-to-Head Stock Analysis & Investment Rating

Last Updated: May 18, 2026

BIIB

62.2
AI Score
VS
BIIB Wins

GSK

54.6
AI Score

Investment Advisor Scores

BIIB

62score
Recommendation
BUY

GSK

55score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric BIIB GSK Winner
Forward P/E 13.8504 9.8135 GSK
PEG Ratio 3.9409 0.4986 GSK
Revenue Growth 1.9% 1.5% BIIB
Earnings Growth 31.1% 8.4% BIIB
Tradestie Score 62.2/100 54.6/100 BIIB
Profit Margin 13.8% 17.8% GSK
Beta 1.00 1.00 Tie
AI Recommendation BUY HOLD BIIB

Frequently Asked Questions

Based on our detailed analysis, BIIB is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.